Products for Research Use Only
RegisterLogin

Daraxonrasib

CAT: 0804-HY-148439-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-148439-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Daraxonrasib (RMC-6236) is an orally active, non-covalent RAS (ON) inhibitor. Daraxonrasib disrupts the interaction of wild-type or mutant RAS proteins with the RAS binding domain of BRAF, with EC50 values ranging from 28-220 nM for wild-type KRAS, NRAS, HRAS, and multiple oncogenic RAS variants. Daraxonrasib inhibits pERK. Daraxonrasib has anti-tumor activity against KRAS mutant tumors[1][2][3].
CAS Number
2765081-21-6
Product Name Alternative
RMC-6236; RAS-IN-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
PERK; Ras
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; GPCR/G Protein; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/rmc-6236.html
Purity
99.88
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(COC([C@H]1NN(C([C@H](CC2=NC3=CS2)NC([C@H]4C[C@@H]4C)=O)=O)CCC1)=O)(C)CC5=[C@@](N(CC)C6=C5C=C3C=C6)[C@@]7=C([C@H](C)OC)N=CC(N8CCN(C)CC8)=C7
Molecular Formula
C44H58N8O5S
Molecular Weight
811.05
Precautions
H302, H315, H319
References & Citations
[1]Jiang J, et al. Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers. Cancer Discov. 2024 Jun 3;14 (6) :994-1017.|[2]Patel H V, et al. The farnesyl transferase inhibitor KO-2806 re-sensitizes relapsing tumors to RAS inhibition. BioRxiv, 2024: 2024.12. 20.629824. |[3]Long SA, et al. Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment. Front Oncol. 2024 May 10;14:1402128.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
K-Ras

Alternative Products

CatalogName
T74698-01Daraxonrasib
E1597-01Daraxonrasib (RMC-6236)

Popular Products